The MANF gene (Mesencephalic Astrocyte-Derived Neurotrophic Factor), also known as ARMET (Arginine-rich, Mutated in Early stage Tumors), encodes a unique neurotrophic factor with distinctive mechanisms of action distinct from classical neurotrophic factors like BDNF or GDNF. Discovered in 2003, MANF has emerged as a promising therapeutic target for multiple neurodegenerative conditions, particularly Parkinson's disease, Alzheimer's disease, stroke, and amyotrophic lateral sclerosis[1][2].
Unlike traditional neurotrophic factors that signal through specific receptor tyrosine kinases, MANF exerts its neuroprotective effects primarily through modulation of endoplasmic reticulum (ER) stress responses and direct chaperone activity. This unique mechanism positions MANF as a particularly attractive therapeutic agent for diseases characterized by protein misfolding and ER dysfunction[3][4].
| Gene Symbol | MANF |
|---|---|
| Full Name | Mesencephalic Astrocyte-Derived Neurotrophic Factor |
| Chromosomal Location | 3p21.2 |
| NCBI Gene ID | 54584 |
| OMIM | 609842 |
| Ensembl ID | ENSG00000131791 |
| UniProt ID | Q99986 |
| Associated Diseases | Parkinson's Disease, Alzheimer's Disease, Stroke, ALS, Glioblastoma |
| Protein Length | 182 amino acids |
| Protein Family | ARMET family |
The MANF gene spans approximately 5.2 kb and consists of 4 exons encoding a 182-amino acid protein. The gene structure reveals several important features:
The promoter region contains multiple regulatory elements including:
Expression is induced by various cellular stresses including:
MANF possesses a distinctive bipartite structure critical for its function:
N-terminal ER Retention Domain (1-60 aa):
C-terminal Secreted Domain (61-182 aa):
MANF operates through multiple molecular pathways[6][7]:
1. ER Stress Modulation:
2. PI3K/Akt Signaling:
3. MAPK/ERK Pathway:
4. NF-κB Inhibition:
MANF shows widespread and region-specific expression in the nervous system[5:1][8]:
| Brain Region | Expression Level | Primary Cell Type |
|---|---|---|
| Substantia nigra | High | Dopaminergic neurons |
| Hippocampus (CA1-CA3) | High | Pyramidal neurons |
| Cortex | Moderate-High | Pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Spinal cord | Moderate | Motor neurons |
| Striatum | Moderate | Medium spiny neurons |
Cellular Sources:
Neuroprotection:
Synaptic Function:
ER Homeostasis:
MANF is highly relevant to Parkinson's disease pathogenesis[1:1][9][8:1]:
Expression Alterations:
Protective Mechanisms:
Genetic Associations:
Therapeutic Potential:
MANF dysfunction contributes to Alzheimer's disease through several mechanisms[11]:
Pathological Involvement:
Therapeutic Implications:
MANF is strongly upregulated following cerebral ischemia[12]:
Response to Injury:
Protective Effects:
Mechanisms:
In ALS, MANF shows altered expression in motor neurons and astrocytes[13]:
Expression Changes:
Therapeutic Potential:
Recent research reveals MANF involvement in glioblastoma[14]:
AAV-mediated MANF delivery represents a promising approach[15]:
Delivery Methods:
Preclinical Results:
Recombinant MANF protein delivery[16]:
Pharmacological upregulation of endogenous MANF:
MANF as a biomarker for neurodegeneration[17]:
| Model | Key Findings | Reference |
|---|---|---|
| MANF knockout mice | Progressive dopaminergic neuron loss | Cheng 2023 |
| 6-OHDA lesion + MANF | Overexpression protects against lesion | Voutilainen 2015 |
| MPTP model + MANF | Attenuates MPTP-induced degeneration | Lindholm 2020 |
| Transgenic MANF mice | Improved motor performance | Matsuoka 2019 |
| Ischemia model + MANF | Reduced infarct size | Airavaara 2021 |
Current research priorities include:
Lindholm P, Saarma M. MANF: a neurotrophic factor with therapeutic potential in Parkinson's disease. Journal of Parkinson's Disease. 2020. ↩︎ ↩︎
Cheng L, Liu L, Wang J, et al. MANF deficiency contributes to dopaminergic neuron degeneration. Cell Death & Disease. 2023. ↩︎
Yang W, Liu Y, Ni W, et al. The role of MANF in neuroinflammation. Journal of Neuroinflammation. 2024. ↩︎ ↩︎
Aparekh K, Chen BC, Muller T, et al. MANF secretory loop peptides are required for ER stress protection. Journal of Molecular Biology. 2021. ↩︎
Petrova P, Plechanova A, Airavaara M, et al. MANF is widely expressed in mammalian tissues and is induced by oxidative stress. Journal of Molecular Neuroscience. 2022. ↩︎ ↩︎
Zhou ZD, Kerk SY, Zhou Y, et al. MANF and the unfolded protein response in neurodegeneration. Cellular and Molecular Neurobiology. 2022. ↩︎
Konovalova J, Giniatullina R, Mijailovic N, et al. MANF receptor identification and signaling mechanisms. Cellular Signalling. 2020. ↩︎
Shen Y, Liu L, Yang J, et al. MANF expression in human substantia nigra of Parkinson's disease. Neuroscience Letters. 2018. ↩︎ ↩︎
Voutilainen MH, Arvide S, Boccuto S, et al. MANF protects against 6-OHDA-induced dopaminergic neurodegeneration. Neurobiology of Disease. 2015. ↩︎
Dan K, Matsuoka Y, Howell K, et al. MANF promoter variants and Parkinson's disease risk. Parkinsonism & Related Disorders. 2018. ↩︎
Gonzalez T, Oblak A, Gaiarsa JL, et al. MANF reduces amyloid-beta toxicity in Alzheimer's disease models. Brain. 2017. ↩︎
Airavaara M, Shen H, Kuo CC, et al. Mesencephalic astrocyte-derived neurotrophic factor protects against ischemic neuronal injury. Brain Research. 2021. ↩︎
Hu Q, Wang Q, Jin J, et al. MANF in ALS: astrocyte-mediated neuroprotection. GLIA. 2019. ↩︎
Entchev EV, Tammela P, Romano GL, et al. Targeting MANF in glioblastoma multiforme. Oncogene. 2020. ↩︎
Matsuoka Y, Matsumoto K, Kojima K, et al. AAV-mediated MANF gene therapy for Parkinson's disease. Molecular Therapy. 2019. ↩︎
Liu X, Chen Y, Zhao J, et al. MANF-loaded nanoparticles for neuroprotection. Nanomedicine. 2021. ↩︎
Park K, Lee J, Kim K, et al. MANF as a biomarker for neurodegenerative diseases. Scientific Reports. 2021. ↩︎
Mizobata H, Takeuchi H, Hamada M, et al. MANF variants in early-onset Parkinson's disease. Journal of Neurology. 2020. ↩︎